Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 97

1.

Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients.

Duffy MJ, Crown J.

Clin Chem. 2019 Jul 17. pii: clinchem.2019.303644. doi: 10.1373/clinchem.2019.303644. [Epub ahead of print]

PMID:
31315901
2.

Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells.

Gaule P, Mukherjee N, Corkery B, Eustace AJ, Gately K, Roche S, O'Connor R, O'Byrne KJ, Walsh N, Duffy MJ, Crown J, O'Donovan N.

Cancers (Basel). 2019 Apr 17;11(4). pii: E548. doi: 10.3390/cancers11040548.

3.

HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells.

McDermott MSJ, Conlon N, Browne BC, Szabo A, Synnott NC, O'Brien NA, Duffy MJ, Crown J, O'Donovan N.

Cancers (Basel). 2019 Feb 8;11(2). pii: E197. doi: 10.3390/cancers11020197.

4.

An individual reference limit of the serum CEA-TPA-CA 15-3 tumor marker panel in the surveillance of asymptomatic women following surgery for primary breast cancer.

Nicolini A, Carpi A, Ferrari P, Morganti R, Mazzotti V, Barak V, Duffy MJ.

Cancer Manag Res. 2018 Dec 13;10:6879-6886. doi: 10.2147/CMAR.S177522. eCollection 2018.

5.

The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells.

Synnott NC, Madden SF, Bykov VJN, Crown J, Wiman KG, Duffy MJ.

Transl Oncol. 2018 Dec;11(6):1343-1349. doi: 10.1016/j.tranon.2018.08.009. Epub 2018 Sep 6.

6.

Tissue and Blood Biomarkers in Lung Cancer: A Review.

Duffy MJ, O'Byrne K.

Adv Clin Chem. 2018;86:1-21. doi: 10.1016/bs.acc.2018.05.001. Epub 2018 May 30. Review.

PMID:
30144837
7.

Circulating tumour DNA as a cancer biomarker.

Duffy MJ.

Ann Clin Biochem. 2019 Jan;56(1):42-48. doi: 10.1177/0004563218798401. Epub 2018 Sep 5.

PMID:
30114930
8.

Blood-based biomarkers in breast cancer: From proteins to circulating tumor cells to circulating tumor DNA.

Duffy MJ, McDermott EW, Crown J.

Tumour Biol. 2018 May;40(5):1010428318776169. doi: 10.1177/1010428318776169. Review.

PMID:
29775157
9.

Mutant p53 in breast cancer: potential as a therapeutic target and biomarker.

Duffy MJ, Synnott NC, Crown J.

Breast Cancer Res Treat. 2018 Jul;170(2):213-219. doi: 10.1007/s10549-018-4753-7. Epub 2018 Mar 21. Review.

PMID:
29564741
10.

Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007.

Synnott NC, Bauer MR, Madden S, Murray A, Klinger R, O'Donovan N, O'Connor D, Gallagher WM, Crown J, Fersht AR, Duffy MJ.

Cancer Lett. 2018 Feb 1;414:99-106. doi: 10.1016/j.canlet.2017.09.053. Epub 2017 Oct 22.

PMID:
29069577
11.

Prognostic and predictive biomarkers in breast cancer: Past, present and future.

Nicolini A, Ferrari P, Duffy MJ.

Semin Cancer Biol. 2018 Oct;52(Pt 1):56-73. doi: 10.1016/j.semcancer.2017.08.010. Epub 2017 Sep 4. Review.

PMID:
28882552
12.

Mutant p53 as a target for cancer treatment.

Duffy MJ, Synnott NC, Crown J.

Eur J Cancer. 2017 Sep;83:258-265. doi: 10.1016/j.ejca.2017.06.023. Epub 2017 Jul 28. Review.

PMID:
28756138
13.

Vitamin D analogues: Potential use in cancer treatment.

Duffy MJ, Murray A, Synnott NC, O'Donovan N, Crown J.

Crit Rev Oncol Hematol. 2017 Apr;112:190-197. doi: 10.1016/j.critrevonc.2017.02.015. Epub 2017 Feb 22. Review.

PMID:
28325259
14.

Vitamin D receptor as a target for breast cancer therapy.

Murray A, Madden SF, Synnott NC, Klinger R, O'Connor D, O'Donovan N, Gallagher W, Crown J, Duffy MJ.

Endocr Relat Cancer. 2017 Apr;24(4):181-195. doi: 10.1530/ERC-16-0463. Epub 2017 Feb 17.

PMID:
28213567
15.

Use of Multiparameter Tests for Identifying Women with Early Breast Cancer Who Do Not Need Adjuvant Chemotherapy.

Duffy MJ, McDermott EW, Crown J.

Clin Chem. 2017 Apr;63(4):804-806. doi: 10.1373/clinchem.2016.267161. Epub 2017 Feb 10. No abstract available.

16.

Validated biomarkers: The key to precision treatment in patients with breast cancer.

Duffy MJ, O'Donovan N, McDermott E, Crown J.

Breast. 2016 Oct;29:192-201. doi: 10.1016/j.breast.2016.07.009. Epub 2016 Aug 9. Review.

PMID:
27521224
17.

The ADAMs family of proteases as targets for the treatment of cancer.

Mullooly M, McGowan PM, Crown J, Duffy MJ.

Cancer Biol Ther. 2016 Aug 2;17(8):870-80. doi: 10.1080/15384047.2016.1177684. Epub 2016 Apr 26. Review.

18.

Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cells.

Caiazza F, Murray A, Madden SF, Synnott NC, Ryan EJ, O'Donovan N, Crown J, Duffy MJ.

Endocr Relat Cancer. 2016 Apr;23(4):323-34. doi: 10.1530/ERC-16-0068. Epub 2016 Mar 1.

PMID:
26932782
19.

Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers.

Sölétormos G, Duffy MJ, Othman Abu Hassan S, Verheijen RH, Tholander B, Bast RC Jr, Gaarenstroom KN, Sturgeon CM, Bonfrer JM, Petersen PH, Troonen H, CarloTorre G, Kanty Kulpa J, Tuxen MK, Molina R.

Int J Gynecol Cancer. 2016 Jan;26(1):43-51. doi: 10.1097/IGC.0000000000000586.

20.

Use of Biomarkers in Screening for Cancer.

Duffy MJ.

Adv Exp Med Biol. 2015;867:27-39. doi: 10.1007/978-94-017-7215-0_3. Review.

PMID:
26530358

Supplemental Content

Loading ...
Support Center